Posts

Showing posts from November, 2019

Bridging the Gap in Personalized Oncology using Omics Data and Epidemiology_Crimson Publishers

Image
Bridging the Gap in Personalized Oncology using Omics Data and Epidemiology by Hassan Adwan in Crimson Publishers: Journal of Cancer Research Crimson Publishers_ Novel Approaches in Cancer Study As Personalized Medicine tailored the field of precision oncology, many challenges have been arising tofulfill the dream of a full personalized health integrated system in cancer therapy. Personalized oncology has been addressed through the past decades in multiple disease and various stages using high throughput technology. This review gives hand on recent advances of personalized oncology in several cancer disease models including leukemia, melanoma, breast cancer, lung cancer, colorectal cancer, and prostate cancer. Moreover, the review enumerates technology-based assessment of personalized biomarkers, including chip micro-array, organ on chip, and next generation sequencing. Meanwhile addressing challenges faced in implementing true personalized health cancer i...

The Potential for Individualization of Neoadjuvant Chemotherapy in Breast Cancer_Crimson Publishers

Image
The Potential for Individualization of Neoadjuvant Chemotherapy in Breast Cancer by Hojouj Mohammad IM in Crimson Publishers: Journal of Cancer Research   Crimson Publishers_ Novel Approaches in Cancer Study The preoperative, or, as it is often called, neoadjuvant chemotherapy (NAPCT) of operable breast cancer (the breast cancer) with affected regional lymph nodes has in its time replaced preoperative radiotherapy, as it has a number of significant advantages over the latter. The most important advantage of NAPCT is its systemic action, which allows to “catching up” with probable distant micro-metastases or circulating tumor cells, while pre-operative radiotherapy has a local effect, and on the systemic level the tumor continues to develop. Despite of the fact that with operative breast cancer the time of NAPCT (before or after the operation) does not affect to the long-term results of treatment, the latter becomes applicable even for operable breast cancer without aff...